GlassScriptPhysician profile
Saul R Lerner
NPI 1922096213
$1,703.50
in general payments reported to CMS, 2019-2025
28 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $69.86 · 2021: $74.97 · 2022: $551 · 2023: $308 · 2024: $343 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $264.54 | 2022-2025 | Veozah |
| Abbvie INC. | $207.89 | 2019-2023 | |
| Pfizer INC. | $142.60 | 2021-2024 | |
| Myovant Sciences INC. | $128.39 | 2022 | |
| Hologic Sales and Service, LLC | $106.19 | 2023-2025 | Acessa Provu System, Novasure, Fluent Fluid Management System |
| Sumitomo Pharma America, INC. | $83.34 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $80.48 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $74.25 | 2021-2023 | |
| Allergan, INC. | $69.54 | 2019-2020 | |
| Exeltis, USA INC. | $53.69 | 2019-2022 | |
| Therapeuticsmd, INC. | $41.21 | 2019-2022 | |
| Meditrina | $41.16 | 2024-2025 | |
| Organon LLC | $40.93 | 2021-2022 | |
| Millicent US INC | $40.73 | 2024 | Femring, Intrarosa |
| Amgen INC. | $39.81 | 2024-2025 | Evenity, Prolia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $36.61 | 2022-2023 | |
| Channel Medsystems, INC. | $36.36 | 2023 | |
| Coopersurgical, INC. | $33.35 | 2024 | Paragard T 380a |
| Agile Therapeutics, INC. | $23.89 | 2021-2022 | |
| Novo Nordisk INC | $23.68 | 2024 | Wegovy |
| Mylan Pharmaceuticals INC. | $22.81 | 2022 | |
| Medtronic, INC. | $22.73 | 2025 | Truclear |
| Smith+Nephew, INC. | $18.43 | 2024 | Pico 14 |
| Heron Therapeutics, INC. | $18.39 | 2022 | |
| Evofem Biosciences, INC. | $16.95 | 2022 | |
| Dysis Medical, INC. | $13.64 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Amag Pharmaceuticals, INC. | $11.05 | 2019 | |
| Lupin INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.